APE1 (apurinic/apyrimidinic endonuclease 1), also known as APEX1 or Ref-1. is a multifunctional enzyme central to DNA repair and redox regulation. Primarily involved in the base excision repair (BER) pathway, APE1 cleaves DNA at abasic sites generated by DNA glycosylases, enabling error-free repair of oxidative or alkylation damage. Beyond its endonuclease activity, APE1 acts as a redox signaling regulator, stabilizing transcription factors like AP-1. NF-κB, and p53 by maintaining their reduced, active states.
APE1 antibodies are essential tools for studying its expression, localization, and function in cellular processes. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate APE1's role in cancer, neurodegenerative diseases, and responses to genotoxic stress. In cancer research, elevated APE1 levels correlate with chemotherapy resistance and poor prognosis, making it a potential therapeutic target.
Commercial APE1 antibodies are typically raised against specific epitopes, with monoclonal and polyclonal variants available. Validation includes testing for cross-reactivity across species (human, mouse, rat) and confirming specificity using knockout controls. Researchers often prioritize antibodies distinguishing between APE1's two functional domains: the N-terminal redox domain and C-terminal repair domain. Proper antibody selection ensures accurate interpretation of APE1's dual roles in genome stability and redox signaling across experimental models.